Summit Street Capital Management LLC Purchases New Shares in United Therapeutics Corporation $UTHR

Summit Street Capital Management LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, Holdings Channel.com reports. The firm purchased 52,789 shares of the biotechnology company’s stock, valued at approximately $28,603,000. United Therapeutics accounts for approximately 4.0% of Summit Street Capital Management LLC’s portfolio, making the stock its 5th largest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. Fiduciary Financial Advisors acquired a new stake in shares of United Therapeutics during the second quarter valued at approximately $30,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.4%

UTHR opened at $516.68 on Thursday. The stock has a fifty day moving average price of $531.06 and a 200 day moving average price of $538.56. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35. The stock has a market cap of $22.16 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.76 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $6.41 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $511.97, for a total transaction of $4,863,715.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $166,105,082.71. The trade was a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 424,075 shares of company stock valued at $227,683,710. 8.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent analyst reports. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research note on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.